|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Granular cell tumor of stomach: A case report and review of literature显示文摘小粒的房间肿瘤(GCT ) 被 Abrikosoff 在 1926 第一次描述。是一个相对稀罕的瘤可以在皮或软纸巾通常发生在许多地点,而是大多数。在胃肠道的 GCT 的出现是稀罕的,财务近似为 8% 所有肿瘤,最普通的地点在之中是食管,而胃的本地化是很稀罕的。胃的 GCT 能是独居的或,更经常,与另外的胃肠的本地化联系了。尽管 GCT 通常是临床上并且组织学地良性的,一些恶意的案例被报导了。组织学地,这些肿瘤由在紧缩的“巢”和为 S-100 蛋白质的组织化学的染色支持的免疫里处理的多角形、纺锤形的房间组成从 Schwann 房间的建议推导。这个肿瘤的正确外科手术前的诊断能仅仅在 50% 所有病人被做,它总是基于内视镜的活体检视。Laparoscopic 或常规楔切除术代表选择的治疗。在这研究,作者与渗透性的模式与胃的一个独居的小粒的房间肿瘤报导了一个 49 岁的女人的一个案例,成功地与外科的切除术对待。文学的评论也有关恶意的形式在诊断标准上与强调被介绍。 | Rosalia Patti Piero Luigi Almasio Gaetano Di Vita | 2006 | World Journal of Gastroenterology2006，12，21： | 26 |
| 2 | Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms:Experience with Rifaximin显示文摘AIM:To estimate the prevalence of small intestinal bacterial overgrowth(SIBO) in our geographical area(Western Sicily,Italy) by means of an observational study,and to gather information on the use of locally active,non-absorbable antibiotics for treatment of SIBO.METHODS:Our survey included 115 patients fulfilling the Rome □ criteria for diagnosis of irritable bowel syndrome(IBS);a total of 97 patients accepted to perform a breath test with lactulose(BTLact),and those who had a positive test,received Rifaximin(Normix,Alfa Wassermann) 1200 mg/d for 7 d;3 wk after the end of treatment,the BTLact was repeated.RESULTS:Based on the BTLact results,SIBO was present in about 56% of IBS patients,and it was responsible for some IBS-related symptoms,such as abdominal bloating and discomfort,and diarrhoea.1-wk treatment with Rifaximin turned the BTLact to negative in about 50% of patients and significantly reduced the symptoms,especially in those patients with an alternated constipation/diarrhoea-variant IBS.CONCLUSION:SIBO should be always suspected in patients with IBS,and a differential diagnosis is done by means of a 'breath test'.Rifaximin may represent a valid approach to the treatment of SIBO. | Sergio Peralta Claudia Cottone Tiziana Doveri Piero Luigi Almasio Antonio Craxi | 2009 | World Journal of Gastroenterology2009，15，21： | 19 |
| 3 | Impact of comorbidities on the severity of chronic hepatitis B at presentation显示文摘AIM:To evaluate the clinical relevance of each cofactor on clinical presentation of chronic hepatitis B.METHODS:Out of 1366 hepatitis B surface antigen(HBsAg) positive subjects consecutively observed in 79 Italian hospitals,53(4.3%) showed as the only cofactor hepatitis D virus(HDV) infection [hepatitis B virus(HBV)/HDV group],130(9.5%) hepatitis C virus(HCV)(group HBV/HCV),6(0.4%) human immunodeficiencyvirus(HIV)(group HBV/HIV),138(10.2%) alcohol abuse(group HBV/alcohol);109(8.0%) subjects had at least two cofactors and 924 were in the cofactor-free(CF) group.RESULTS:Compared with patients in group CF those in group HBV/alcohol were older and more frequently had cirrhosis(P < 0.001),those in group HBV/HDV were younger(P < 0.001),more frequently resided in the south of the country and had cirrhosis(P <0.001),those in group HBV/HCV were older(P < 0.001) and more frequently had cirrhosis(P < 0.001).These cofactors were all independent predictors of liver cirrhosis in HBsAg positive patients.Multivariate analysis showed that an older age [odds ratio(OR) 1.06,95% CI:1.05-1.08],alcohol abuse with more than 8 drinks daily(OR 2.89,95% CI:1.81-4.62) and anti-HDV positivity(OR 3.48,95% CI:2.16-5.58) are all independently associated with liver cirrhosis.This association was found also for anti-HCV positivity in univariate analysis,but it was no longer associated(OR 1.23,95% CI:0.84-1.80) at multivariate analysis.CONCLUSION:Older age,HDV infection and alcohol abuse are the major determinants of severe liver disease in chronic HBV infection,while HCV replication plays a lesser role in the severity of hepatic damage. | Evangelista Sagnelli Tommaso Stroffolini Alfonso Mele Michele Imparato Caterina Sagnelli Nicola Coppola Piero Luigi Almasio | 2012 | World Journal of Gastroenterology2012，18，14： | 4 |
| 4 | clinical course and prognostic factors of hepatorenal syndrome:a retrospective single-center cohort study显示文摘AIM: To investigate clinical and biochemical features of hepatorenal syndrome(HRS), to assess short and long- term survival evaluating potential predictors of early mortality. METHODS: Sixty-two patients with liver cirrhosis and renal failure, defined as a serum creatinine value > 1.5 mg/dL on at least two measurements within 48 h, admitted to our tertiary referral Unit from 2001 to 201, were retrospectively reviewed. Among them, 33 patients(53.2%) fulfilled the revised criteria of the International Ascites Club for the diagnosis of HRS. Twenty-eight patients were treated with combinations of terlipressin and albumin, two with dopamine and al- bumin, and three with albumin alone. No patients were suitable for liver transplantation. Complete response was defined as normalization of creatinine levels to less than 1.5 mg/dL, partial response as a decrease of at least 50% but not to less than 1.5 mg/dL, no response as no reduction in creatinine or a decrease of less 50% compared to pre-treatment values. All of the patients were followed up for at least 1 year until January 2013. RESULTS: HRS type 1 was diagnosed in 15 patients(45.5%). Hepatitis C virus infection was the primary etiology(69.6%), followed by alcohol(15.2%), and cryptogenesis(15.2%). Complete response to therapy was obtained in only 3 cases(9.1%) and partial re- sponse in 7 patients(21.2%). Median survival was 30 d(range: 10-274) without significant differences be- tween type 1 and type 2 HRS. By univariate analysis, Child-Pugh class C(P = 0.009), presence of hepatocel- lular carcinoma(P = 0.04), low serum sodium(P = 0.02), high bilirubin values(P = 0.009) and high Model for End-stage Liver Disease(MELD) score(P = 0.03) were predictive factors of 30-d mortality. By multivari- ate analysis, only serum sodium < 132 mEq/L(OR = 31.39; P = 0.02) and MELD score > 27(OR = 18.72; P = 0.01) were independently associated with a survival of less than one month. CONCLUSION: HRS still has a poor prognosis, even when vasoactive drug therapies are extensively used. | Anna Licata Marcello Maida Ambra Bonaccorso Fabio Salvatore Macaluso Maria Cappello Antonio Craxì Piero Luigi Almasio | 2013 | World Journal of Hepatology2013，5，12： | 2 |
| 5 | Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients显示文摘 | G Fattovich G Giustina F Degos F Tremolada G Diodati P Almasio F Nevens A Solinas D Mura JT Brouwer H Thomas C Njapoum C Casarin P Bonetti P Fuschi J Basho A Tocco A Bhalla R Galassini F Noventa SW Schalm G Realdi | 1997 | Gastroenterology1997，，2： | 2 |
| 6 | Serum Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) in Children with Chronic Hepatitis C: Relation to Liver Fibrosis and Viremia显示文摘 | Mostafa M. Sira Behairy E. Behairy Azza M. Abd-Elaziz Sameh A. Abd Elnaby Ehab E. Eltahan Piero Luigi Almasio | 2014 | Hepatitis Research and Treatment2014，，： | 2 |
| 7 | Interleukin-16 Gene Polymorphisms Are Considerable Host Genetic Factors for Patients’ Susceptibility to Chronic Hepatitis B Infection显示文摘 | Sara Romani Seyed Masoud Hosseini Seyed Reza Mohebbi Shabnam Kazemian Shaghayegh Derakhshani Mahsa Khanyaghma Pedram Azimzadeh Afsaneh Sharifian Mohammad Reza Zali Piero Luigi Almasio | 2014 | Hepatitis Research and Treatment2014，，： | 2 |
| 8 | Multicentre survey of the prevalence of intrahepatfc cholestasis in 2 520 conservative patients with newly diagnosed chronic Liver Disease 显示文摘 | BOTROLINI ALMASIO P BRAY G | 1992 | Drug Invest1992，4，4： | 1 |
| 9 | Inguinal hernioplasty improves the quality of life in patients with cirrhosis显示文摘 | Patti R Almasio PL Buscemi S | 2008 | Am J Surg2008，196，3： | 1 |
| 10 | Peg-in-terferon alone or combinedwith ribavirin in HCV cirrhosiswith portalhypertension:a randomized controlled trial显示文摘 | Dimarco V Almasio PL Ferraro D | 2007 | Hepatology2007，47，4： | 1 |
| 11 | Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis 显示文摘 | Almasio P Bortolini M Pagliaro L | 1990 | Drugs1990，40，3： | 1 |
| 12 | Diagnostic approach to liver enzyme elevation显示文摘 | Craxi A Almasio P | 1996 | J Hepatol1996，25，1： | 1 |
| 13 | Multicentre Survey of the Prevalence of intrahepatic cholestasis in 2520 consecutive patients with newly diagnosed chronic liver disease显示文摘 | Almasio P Bray G | 1992 | Drug Invest1992，4，4： | 1 |
| 14 | Multicentre survey of the prevalence of intrahepatic cholestasis in 2520 consecutive patients with newly diagnosed chronic liver disease显示文摘 | Bortolini M Almasio P Bray G | 1992 | Drug Invest1992，4，4： | 1 |
| 15 | Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients显示文摘 | G Fattovich G Giustina F Degos F Tremolada G Diodati P Almasio F Nevens A Solinas D Mura JT Brouwer H Thomas C Njapoum C Casarin P Bonetti P Fuschi J Basho A Tocco A Bhalla R Galassini F Noventa SW Schalm G Realdi | 1997 | Gastroenterology1997，，2： | 1 |
| 16 | Multicentre survey of the prevalence of intrahepatic cholestasis in 2520 consecutive patients with newly diagnosed chronic liver disease 显示文摘 | Bortolini M Almasio P Bray G | 1992 | Drug Investigation1992，4，4： | 1 |
| 17 | Multicentre survey of the prevrlence of intrahepatic cholestasis in 2520 consecutive patients with newly diagnosed chronic liver disease显示文摘 | Bortolini M Almasio P Bray G | 1992 | Drug Invest1992，4，14： | 1 |
| 18 | Diagnostic approach to liver enzyme elevation 显示文摘 | Craxi A Almasio P | 1996 | J Hepatol1996，，： | 1 |
| 19 | Isolation and growth of human endothelial cells from peripheral blood by PVP - silica gradients显示文摘 | SAMADEN PIOVELLA F ALMASIO P | 1985 | Boll Soc Ital Biol Sper1985，61，7： | 1 |
| 20 | Current practice of chronic hepatitis B treatment in Southern Italy显示文摘 | T. Stroffolini A. Spadaro V. Di Marco G. Scifo M. Russello G. Montalto G. Bertino L. Surace B. Caroleo G. Foti V. Portelli S. Madonia M. Sapienza L. Cosco P. Frugiuele A. Galdieri N. Brandolino R. Siciliano S. Bruno P.L. Almasio | 2012 | European Journal of Internal Medicine2012，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员